Production of Monoclonal Antibodies in Plants for Cancer Immunotherapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Moussavou, Ghislain ^a   Ko, Kisung ^b   Lee, Jeong Hwan ^b   Choo, Young Kug ^c  

^a SolarLight Ltd   (South Korea)

^b Chung Ang University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; CANCER VACCINE;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BIOMASS PRODUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG PURIFICATION; ENVIRONMENTAL IMPACT; GENETIC RESOURCE; HUMAN; IN VITRO STUDY; NONHUMAN; PLANT; PLANT LEAF; PLANT ROOT; PLANT STEM; PROTEIN EXPRESSION; REVIEW; SPECIES DIVERSITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; PROTEIN ENGINEERING; TRANSGENIC PLANT; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PLANTS, GENETICALLY MODIFIED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84945922782     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/306164     Document Type: Review

References (86)

1. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008," International Journal ofCancer, vol. 127, no. 12, pp. 2893-2917, 2010.
2. D. M. Pereira, J. Cheel, P. B. Andrade et al., "Anti-proliferative activity of meroditerpenoids isolated from the brown alga Stypopodium flabelliforme against several cancer cell lines," Marine Drugs, vol. 9, no. 5, pp. 852-862, 2011.
3. J. R. Mann,M. G. Backlund, and R. N. DuBois, "Mechanisms of disease: inflammatory mediators and cancer prevention," Nature Clinical Practice Oncology, vol. 2, no. 4, pp. 202-210, 2005.
4. A. M. Scott, J. D. Wolchok, and L. J. Old, "Antibody therapy of cancer," Nature Reviews Cancer, vol. 12, no. 4, pp. 278-287, 2012.
5. K. Ko, R. Brodzik, and Z. Steplewski, "Production of antibodies in plants: approaches and perspectives," Current Topics in Microbiology and Immunology, vol. 332, pp. 55-78, 2010.
6. A. H. Horwitz, C. P. Chang,M. Better,K. E. Hellstrom, and R. R. Robinson, "Secretion of functional antibody and Fab fragment fromyeast cells," Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 85, no. 22, pp. 8678-8682, 1988.
7. D.-S. Kim, L. Qiao, K.-J. Lee, and K. Ko, "Optimization of colorectal cancer vaccine candidate protein GA733-Fc expression in a baculovirus-insect cell system," Entomological Research, vol. 45, no. 1, pp. 39-48, 2015.
8. H.-S. Kim, J.-H. Jeon, K. J. Lee, and K. Ko, "N-glycosylation modification of plant-derived virus-like particles: an application in vaccines," BioMed Research International, vol. 2014, Article ID 249519, 8 pages, 2014.
9. K. Kisung, "Expression of recombinant vaccines and antibodies in plants," Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, vol. 33, no. 3, pp. 192-198, 2014.
10. J.-H. Lee, D.-Y. Park, K.-J. Lee et al., "Intracellular reprogramming of expression, glycosylation, and function of a plantderived antiviral therapeuticmonoclonal antibody," PLoS ONE, vol. 8, no. 8, Article ID e68772, 2013.
11. J.-H. Lee, K.-A. Hwang, S. S. Park, Y.-K. Choo, and K. Ko, "Expression of recombinant anti-breast cancer immunotherapeutic monoclonal antibody in baculovirus-insect cell system," Entomological Research, vol. 44, no. 5, pp. 207-214, 2014.
12. C.-Y. Lim, D.-S. Kim, K. J. Lee, K.-A. Hwang, Y.-K. Choo, and K. Ko, "Optimization of storage temperature for the pollen viability of transgenic plants that express the anti-breast cancer monoclonal antibody mAb BR55," Plant Omics, vol. 7, no. 5, pp. 403-409, 2015.
13. S.-R. Park, Y. K. Shin, K. J. Lee et al., "Expression, glycosylation and function of recombinant anti-colorectal cancermAb CO17-1A in SfSWT4 insect cells," Entomological Research, vol. 44, no. 1, pp. 39-46, 2014.
14. J. K.-C. Ma, P. M. W. Drake, and P. Christou, "The production of recombinant pharmaceutical proteins in plants," Nature Reviews Genetics, vol. 4, no. 10, pp. 794-805, 2003.
15. V. Gomord, C. Sourrouille, A.-C. Fitchette et al., "Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge," Plant Biotechnology Journal, vol. 2, no. 2, pp. 83-100, 2004.
16. K. Ko and H. Koprowski, "Plant biopharming of monoclonal antibodies," Virus Research, vol. 111, no. 1, pp. 93-100, 2005.
17. D. Brenner and T. W. Mak, "Mitochondrial cell death effectors," Current Opinion in Cell Biology, vol. 21, no. 6, pp. 871-877, 2009.
18. Y. So, K.-J. Lee, D.-S. Kim et al., "Glycomodification and characterization of anti-colorectal cancer immunotherapeutic monoclonal antibodies in transgenic tobacco," Plant Cell, Tissue and Organ Culture, vol. 113, no. 1, pp. 41-49, 2013.
19. L. Zeitlin, S. S. Olmsted, K. J. Whaley et al., "A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes," Nature Biotechnology, vol. 16, no. 13, pp. 1361-1364, 1998.
20. K. Ko, Y. Tekoah, P. M. Rudd et al., "Function and glycosylation of plant-derived antiviral monoclonal antibody," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 13, pp. 8013-8018, 2003.
21. A. Castilho, N. Bohorova, J. Grass et al., "Rapid high yield production of different glycoforms of ebola virus monoclonal antibody," PLoS ONE, vol. 6, no. 10, Article IDe26040, 2011.
22. X. Qiu, G. Wong, J. Audet et al., "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp," Nature, vol. 514, no. 7520, pp. 47-53, 2014.
23. Y. Rosenberg, M. Sack, X. Jiang et al., "Rapid high-level production of functionalHIV broadly neutralizingmonoclonal antibodies in transient plant expression systems," PLoS ONE, vol. 8, no. 3, Article IDe58724, 2013.
24. L. Zeitlin, O. Bohorov, N. Bohorova et al., "Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model," mAbs, vol. 5, no. 2, pp. 263-269, 2013.
25. H. Lai, J. He, J. Hurtado et al., "Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants," Plant Biotechnology Journal, vol. 12, pp. 1098-1107, 2014.
26. C. Vaquero, M. Sack, J. Chandler et al., "Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11128-11133, 1999.
27. E. Torres, C. Vaquero, L. Nicholson et al., "Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies," Transgenic Research, vol. 8, no. 6, pp. 441-449, 1999.
28. E. Stöger, C. Vaquero, E. Torres et al., "Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies," Plant Molecular Biology, vol. 42, no. 4, pp. 583-590, 2000.
29. R. Brodzik, M. Glogowska, K. Bandurska et al., "Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 23, pp. 8804-8809, 2006.
30. K. Ko, Z. Steplewski, M. Glogowska, and H. Koprowski, "Inhibition of tumor growth by plant-derived mAb," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 7026-7030, 2005.
31. J. K.-C. Ma, A. Hiatt, T. Lehner et al., "Generation and assembly of secretory antibodies in plants," Science, vol. 268, no. 5211, pp. 716-719, 1995.
32. K. L. Wycoff, "Secretory IgA antibodies from plants," Current Pharmaceutical Design, vol. 11, no. 19, pp. 2429-2437, 2005.
33. J. K.-C. Ma, B. Y. Hikmat, K. Wycoff et al., "Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans," Nature Medicine, vol. 4, no. 5, pp. 601-606, 1998.
34. A. K. Hull, C. J. Criscuolo,V. Mett et al., "Human-derived,plantproduced monoclonal antibody for the treatment of anthrax," Vaccine, vol. 23, no. 17-18, pp. 2082-2086, 2005.
35. A. Iannello and A. Ahmad, "Role of antibody-dependent cellmediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies," Cancer andMetastasis Reviews, vol. 24, no. 4, pp. 487-499, 2005.
36. E. S. Vitetta and J. W. Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," Cancer Research, vol. 54, no. 20, pp. 5301-5309, 1994.
37. W. M. J. Vuist, R. Levy, and D. G. Maloney, "Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein," Blood, vol. 83, no. 4, pp. 899-906, 1994.
38. M. J. Coloma, R. K. Trinh, A. R. Martinez, and S. L. Morrison, "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1 ? 6) dextran antibody," The Journal of Immunology, vol. 162, no. 4, pp. 2162-2170, 1999.
39. H. Tachibana, S. Shirahata, and H. Murakami, "Generation of specificity-variant antibodies by alteration of carbohydrate in light chain of human monoclonal antibodies," Biochemical and Biophysical Research Communications, vol. 189, no. 2, pp. 625-632, 1992.
40. K. Ko, M.-H. Ahn, H. Joung, and et al, "Glyco-engineering of biotherapeutic proteins in plants," Molecules and Cells, vol. 25, no. 4, pp. 494-503, 2008.
41. H. Koprowski, Z. Steplewski, K. Mitchell, M. Herlyn, D. Herlyn, and P. Fuhrer, "Colorectal carcinoma antigens detected by hybridoma antibodies," Somatic Cell Genetics, vol. 5, no. 6, pp. 957-971, 1979.
42. G. Riethmuller, R. Gruber, E. Schneider-Gadicke et al., "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," The Lancet, vol. 343, no. 8907, pp. 1177-1183, 1994.
43. G. Riethmüller, E. Holz, G. Schlimok et al., "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: sevenyear outcome of amulticenter randomized trial," Journal ofClinical Oncology, vol. 16, no. 5, pp. 1788-1794, 1998.
44. T. Verch,V. Yusibov, and H. Koprowski, "Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector," Journal of Immunological Methods, vol. 220, no. 1-2, pp. 69-75, 1998.
45. B. Fernandes, U. Sagman, M. Auger, M. Demetrio, and J. W. Dennis, "Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia," Cancer Research, vol. 51, no. 2, pp. 718-723, 1991.
46. Y. Nemoto-Sasaki, M. Mitsuki, M. Morimoto-Tomita, A. Maeda, M. Tsuiji, and T. Irimura, "Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in amouse model," Glycoconjugate Journal, vol. 18, no. 11-12, pp. 895-906, 2001.
47. E. J. Nichols, R. Kannagi, S.-I. Hakomori, M. J. Krantz, and A. Fuks, "Carbohydrate determinants associated with carcinoembryonic antigen (CEA),"The Journal of Immunology, vol. 135, no. 3, pp. 1911-1913, 1985.
48. Z. Steplewski, L. K. Sun, C. W. Shearman, J. Ghrayeb, P. Daddona, and H. Koprowski, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 13, pp. 4852-4856, 1988.
49. Z. Steplewski, M. D. Lubeck, and H. Koprowski, "Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells," Science, vol. 221, no. 4613, pp. 865-867, 1983.
50. A. Jamal, J.-H. Lee, K. Ko et al., "Chimerismof multiple monoclonal antibodies expressed in a single plant," Horticulture Environment and Biotechnology, vol. 53,no. 6, pp. 544-551, 2012.
51. H. E. Chadd and S. M. Chamow, "Therapeutic antibody expression technology," Current Opinion in Biotechnology, vol. 12, no. 2, pp. 188-194, 2001.
52. C.-Y. Lim, K. J. Lee, D.-B. Oh, and K. Ko, "Effect of the developmental stage and tissue position on the expression and glycosylation of recombinant glycoprotein GA733-FcK in transgenic plants," Frontiers in Plant Science, vol. 5, article 778, 11 pages, 2015.
53. L. Faye, N. Landry, P. Lerouge, V. Gomord, and L. Vézina, "La production de protéines à usage biopharmaceutique dans les plantes,"Médecine/Sciences SYNTHESE, vol. 17,no. 8-9, pp. 867-877, 2012.
54. I. C. Song, D. S. Kim, M. K. Kim, A. Jamal, K.-A. Hwang, and K. Ko, "Comparison of total soluble protein in various horticultural crops and evaluation of its quantification methods," Horticulture, Environment, and Biotechnology, vol. 56, no. 1, pp. 123-129, 2015.
55. K. Ko, X. Wei, P. A. Crooks, and H. Koprowski, "Elimination of alkaloids from plant-derived human monoclonal antibody," Journal of Immunological Methods, vol. 286, no. 1-2, pp. 79-85, 2004.
56. M. Cabanes-Macheteau, A.-C. Fitchette-Lainé, C. Loutelier-Bourhis et al., "N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants," Glycobiology, vol. 9, no. 4, pp. 365-372, 1999.
57. R. Fischer, E. Stoger, S. Schillberg, P. Christou, and R. M. Twyman, "Plant-based production of biopharmaceuticals," Current Opinion in Plant Biology, vol. 7, no. 2, pp. 152-158, 2004.
58. L. Faye, A. Boulaflous, M. Benchabane, V. Gomord, and D. Michaud, "Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming," Vaccine, vol. 23, no. 15, pp. 1770-1778, 2005.
59. R. Fischer and N. Emans, "Molecular farming of pharmaceutical proteins," Transgenic Research, vol. 9, no. 4-5, pp. 279-299, 2000.
60. C. Robaglia andC. Vriet, "Prodcutiondemolecules d'interêt par les plantes 'plant molecular farming'," in M1 MBVB-UE Biotechnologie Microbienne et Végétale, ATER 2014, 2014.
61. C. Rayon, M. Cabanes-Macheteau, L. Faye et al., "Characterization of N-glycans from Arabidopsis. Application to a fucosedeficient mutant," Plant Physiology, vol. 119, no. 2, pp. 725-733, 1999.
62. L. Faye and M. J. Chrispeels, "Common antigenic determinants in the glycoproteins of plants, molluscs and insects," Glycoconjugate Journal, vol. 5, no. 3, pp. 245-256, 1988.
63. R. Van Ree,M. Cabanes-Macheteau, J. Akkerdaas et al., "(1,2)-xylose and (1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens," The Journal of Biological Chemistry, vol. 275, no. 15, pp. 11451-11458, 2000.
64. I. B. H. Wilson and F. Altmann, "Structural analysis of Nglycans from allergenic grass, ragweed and tree pollens: core 1,3-linked fucose and xylose present in all pollens examined," Glycoconjugate Journal, vol. 15, no. 11, pp. 1055-1070, 1998.
65. A. R. Kermode, "Mechanisms of intracellular protein transport and targeting in plant cells," Critical Reviews in Plant Sciences, vol. 15, no. 4, pp. 285-423, 1996.
66. R. L. Shields, J. Lai, R. Keck et al., "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRIII and antibody-dependent cellular toxicity," Journal of Biological Chemistry, vol. 277, no. 30, pp. 26733-26740, 2002.
67. D. M. Herlyn, Z. Steplewski, M. F. Herlyn, and H. Koprowski, "Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody," Cancer Research, vol. 40, no. 3, pp. 717-721, 1980.
68. J.-L. Verdeil, L. Alemanno, N. Niemenak, and T. J. Tranbarger, "Pluripotent versus totipotent plant stem cells: dependence versus autonomy?" Trends in Plant Science, vol. 12, no. 6, pp. 245-252, 2007.
69. T. V. Komarova, S. Baschieri, M. Donini, C. Marusic, E. Benvenuto, and Y. L. Dorokhov, "Transient expression systems for plant-derived biopharmaceuticals," Expert Review of Vaccines, vol. 9, no. 8, pp. 859-876, 2010.
70. H. Daniell, "Medical molecular pharming: expression of antibodies, biopharmaceuticals and edible vaccines via the chloroplast genome," in Plant Biotechnology 2002 and Beyond, pp. 371-376, Springer, Dordrecht,The Netherlands, 2003.
71. S. Kathuria, R. Sriraman, R. Nath et al., "Efficacy of plantproduced recombinant antibodies against HCG," Human Reproduction, vol. 17, no. 8, pp. 2054-2061, 2002.
72. A. Loos, C. Gruber, F. Altmann et al., "Expression and glycoengineering of functionally active heteromultimeric IgM in plants," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 17, pp. 6263-6268, 2014.
73. B. Nagels, E. J. M. VanDamme,M. Pabst,N. Callewaert, and K. Weterings, "Production of complex multiantennary N-glycans in Nicotiana benthamiana plants," Plant Physiology, vol. 155, no. 3, pp. 1103-1112, 2011.
74. A. A. McCormick, M. H. Kumagai, R. Levy et al., "Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 2, pp. 703-708, 1999.
75. B. Gronenborn and V. Matzeit, "Plant gene vectors and genetic transformation: plant viruses as vectors," inMolecular Biology of Plant Nuclear Genes, vol. 6, chapter 4, pp. 69-100, Elsevier, 1989.
76. J. Xu,M. C. Dolan, G. Medrano, C. L. Cramer, and P. J. Weathers, "Green factory: plants as bioproduction platforms for recombinant proteins," Biotechnology Advances, vol. 30, no. 5, pp. 1171-1184, 2012.
77. R. Valdés, L. Gómez, S. Padilla et al., "Large-scale purification of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants," Biochemical and Biophysical Research Communications, vol. 308, no. 1, pp. 94-100, 2003.
78. M. D. McLean, R. Chen, D. Yu et al., "Purification of the therapeutic antibody trastuzumab from genetically modified plants using safflower Protein A-oleosin oilbody technology," Transgenic Research, vol. 21, no. 6, pp. 1291-1301, 2012.
79. J. G. Boothe, J. A. Saponja, and D. L. Parmenter, "Molecular farming in plants: oilseeds as vehicles for the production of pharmaceutical proteins," Drug Development Research, vol. 42, no. 3-4, pp. 172-181, 1997.
80. J. H. Seon, S. Szarka, and M. Moloney, "A unique strategy for recovering recombinant proteins from molecular farming: affinity capture on engineered oilbodies," Plant Biotechnology Journal, vol. 4, pp. 95-101, 2002.
81. M. Torrent, B. Llompart, S. Lasserre-Ramassamy et al., "Eukaryotic protein production in designed storage organelles," BMC Biology, vol. 7, article 5, 2009.
82. W. Hassouneh, T. Christensen, and A. Chilkoti, "UNIT 6. 11 Elastin-like polypeptides as a purification tag for recombinant proteins," in Current Protocols in Protein Science, chapter 6, John Wiley & Sons, 2010.
83. S. R. MacEwan,W. Hassouneh, and A. Chilkoti, "Non-chromatographic purification of recombinant elastin-like polypeptides and their fusions with peptides and proteins from Escherichia coli," Journal of Visualized Experiments, no. 88, Article ID e51583, 2014.
84. M. B. Linder,M. Qiao, F. Laumen et al., "Efficient purification of recombinant proteins using hydrophobins as tags in surfactantbased two-phase systems," Biochemistry, vol. 43, no. 37, pp. 11873-11882, 2004.
85. M. B. Linder, "Hydrophobins: proteins that self assemble at interfaces," CurrentOpinion in Colloid and Interface Science, vol. 14, no. 5, pp. 356-363, 2009.
86. J. J. Joensuu,A. J. Conley,M. B. Linder, and R. Menassa, "Bioseparation of recombinant proteins from plant extract with hydrophobin fusion technology," Methods in Molecular Biology, vol. 824, pp. 527-534, 2012.